期刊文献+

卡托普利对高血压冠状动脉壁肥厚和储备力下降的预防作用 被引量:3

Effects of Captopril on Hypertrophy and Reducing Reserve of Coronary Arteries in Hypertension
下载PDF
导出
摘要 目的研究卡托普利对高血压冠状动脉壁肥厚和储备力下降的预防作用。方法4w大鼠设3组:分别为自发性高血压大鼠(SHR)组、SHR口服卡托普利组(SHR+C)和正常血压大鼠(WKY)组,饲养12w。结果SHR+C组较SHR组,收缩压、冠状动脉壁横截面积、横截面积与内径比及中层血管平滑肌细胞宽度显著下降,最大冠状动脉流量增加,与WKY组无显著差异。结论卡托普利能完全预防SHR冠状动脉壁肥厚和储备力下降。 Objective\ To study effects of captopril on left ventricular hypertrophy and the reduced reserve of coronary arteries in hypertension.\ Methods\ 4 week old rats were divided into three groups: spontaneously hypertensive rats(SHR) group, SHR+captopril(SHR+C,40mg/kg qd) group and normtensive Wistar Kyoto rats(WKY) group. Systolic blood pressure(SBP) was measured. Maximal coronary flow(MCF) was measured by using an isolated perfused rat heart model. Cross sectional area(CSA) and CSA/lumen diameter(CSA/LD) of coronary arteries were analysed by computer, and morphology of vascular smooth muscle cells(VSMC) of the left anterior descending coronary artery was investigate by electromicroscopy.\ Results\ Compared with SHR group,SBP, CSA, CSA/LD and the size of VSMC reduced significantly in SHR+C group. In addition, MCF increased greatly in SHR+C group(34.9±3.24 ml·min -1 ·g -1 ) compared with SHR group(23.3±1.99 ml·min -1 ·g -1 ).\ Conclusion\ Captopril could effectively prevent the hypertrophy and improve the reducing reserve of coronary arteries in SHR.
出处 《高血压杂志》 CSCD 1999年第1期39-42,共4页 Chinese Journal of Hypertension
关键词 冠状动脉 高血压 卡托普利 动脉壁肥厚 储备力 coronary hypertension captopril
  • 相关文献

参考文献3

共引文献18

同被引文献21

  • 1董晓雁 程红英 韩斌 等.心力衰竭时内皮素与肾素活性的关系及转换酶抑制剂的影响(摘要)[J].中华心血管病杂志,1994,22(3):229-229.
  • 2章建梁,杨向群.高血压血管重构[J].国外医学(心血管疾病分册),1997,24(1):26-29. 被引量:11
  • 3Struyker-Boudier HAJ, Van-Bortel LMA, De-Mey JGR. Remodeling of the vascular tree in hypertension: drug effects[J]. Trends Pharmacol Sci, 1990,11 (3) :240 - 244.
  • 4Anderson FG,Bishop SP, Digemess SB. Vascular remodeling and improverment of coronary reserve after hydralazine treatment in spontaneously hypertensive rats[J]. Girc Res,1989,64(6) :1127-1136.
  • 5Raasch W, Bartels T, Schwartz C, et al. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors[ J ]. J Hypertens,2002,20(12) :2495 - 2504.
  • 6Amann K,Gharehbaghi H, Stephen S, et al.Hypertrophy and hyperplasia of smooth muscle cells of intramyocrdial arteries in spontanously hypertensive rats[J].Hypertension,1995,25(1):124-131.
  • 7Iriarte MM, Caso R, Murga N, etal. Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril[J]. Am J Cardiol, 1995,76(13) :31D- 34D.
  • 8ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholestemlemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) [ J ]. JAMA, 2002,288(23) :2998 - 3007.
  • 9ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertansive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)[J]. JAMA ,2002,288(23) :2981 - 2997.
  • 10胡大一,刘晓惠.β-阻滞剂在充血性心力衰竭治疗中的应用[J].临床心血管病杂志,1998,14(3):187-189. 被引量:76

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部